云顶新耀:“第二增长曲线”已成

建国路128号
Feb 11

2026年2月,医药二级市场还在调整期,云顶新耀的一笔交易引起了不少讨论。公司宣布以2亿元人民币的首付款(总交易额12.4亿),引进了麦科奥特处于临床III期的核心管线MT1013。在大多数Biotech都在收缩战线、捂紧钱袋子的当下,云顶新耀这种逆势“扫货”的动作,有点特别。几乎同一时间,另一则消息落地:公司旗下的自免药物维适平®(精氨酸艾曲莫德片)正式拿到CDE的上市许可,用于治疗对传统治疗或...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10